Recce Pharmaceuticals Ltd. announced the China National Intellectual Property Administration has formally granted Recce a new family two patent, Copolymer and Method for Treatment of Bacterial Infection, for its anti-infectives, with expiry in 2035. This is the final of Recce?s wholly-owned patents granted for family two, with the Company now patent-protected in all major pharmaceutical markets globally. The Chinese patent claims relate to RECCE 327 (R327) and RECCE 529 (R529), including their methods of manufacture, administration, and application to treat a broad range of common human infections.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.6 AUD | +3.45% | +0.84% | +12.15% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+12.15% | 78.37M | |
+38.51% | 728B | |
+33.05% | 603B | |
-6.23% | 360B | |
+18.78% | 332B | |
+1.35% | 279B | |
+16.00% | 244B | |
+8.09% | 207B | |
-5.77% | 205B | |
+6.19% | 164B |
- Stock Market
- Equities
- RCE Stock
- News Recce Pharmaceuticals Ltd
- Recce Pharmaceuticals Ltd Receives New Patent in China for RECCE Anti-Infectives from China National Intellectual Property Administration